KUALA LUMPUR (Feb 16): Biotechnology company Moderna Inc is expanding its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. The company said the Asia-Pacific region represents an integral part of Moderna's business, with established subsidiaries in Japan, South Korea, and Australia. Bancel said Asia bears the highest burden of infectious diseases, and the burden of non-communicable diseases is increasing as the population ages. He said regulators have approved Moderna's Covid-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of Moderna's Covid-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets, he said.

Source: The Edge Markets February 16, 2022 04:37 UTC